NCT06465030

Brief Summary

The study will evaluate the local experiences in treatment of head and neck carcinoma by retrospectively analyzing the incidence and location of recurrence, and also studying factors affecting this recurrence.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
35

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 29, 2024

Completed
20 days until next milestone

First Posted

Study publicly available on registry

June 18, 2024

Completed
27 days until next milestone

Study Start

First participant enrolled

July 15, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

June 25, 2024

Status Verified

May 1, 2024

Enrollment Period

9 months

First QC Date

May 29, 2024

Last Update Submit

June 21, 2024

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

  • Pattern of relapse in recurrent head and neck squamous cell carcinoma, evident clinically and measured by images "US,CT, MRI and endoscopy".

    Local, locoregional recurrence by MRI neck and CT Neck and distant recurrence by pan CTs.

    At least obsevation of 1 year FU of the patient

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with recurrent head and neck cancer after radical treatment by IMRT and VMAT, in Sohag city.

You may qualify if:

  • Adults aged more than 18 years. Patients with primary non nasopharyngeal head and neck squamous cell carcinoma. Patients who were intended to receive radical treatment delivered by IMRT and VMAT techniques.

You may not qualify if:

  • Adults who had double malignancies. Metastatic HNSCC cases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag Faculty of Medicine

Sohag, Egypt

RECRUITING

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck

Condition Hierarchy (Ancestors)

Carcinoma, Squamous CellCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsHead and Neck NeoplasmsNeoplasms by Site

Study Officials

  • Reem Gamal, M.B.B.Ch

    Sohag university hospital, oncology and nuclear medicine department

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Reem Gamal, M.B.B.Ch

CONTACT

01094086660reemgamal4996@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
RESIDENT

Study Record Dates

First Submitted

May 29, 2024

First Posted

June 18, 2024

Study Start

July 15, 2024

Primary Completion

April 1, 2025

Study Completion

June 1, 2025

Last Updated

June 25, 2024

Record last verified: 2024-05

Locations

EG(1)